Proposals are also welcome for highly novel drug targets involved in neuropathic pain or neuroprotection.
Daiichi Sankyo (DS) has designated pain therapy as a priority area and aims to contribute to the improvement of future medical treatment by precisely identifying unmet medical needs and focusing their research and development on drugs that satisfy those needs.
DS has decided to issue this open request with the aim of developing innovative new drugs by combining its advanced knowledge and capability for new drug development in the field of pain held by their promising partner organization.
Insight on how peripheral neuropathy provokes pain in CIPN or post-operative neuropathy has been rapidly progressing, and development of innovative new drugs is eagerly anticipated. However, their pathogenic mechanism is highly complicated and there remain problems in developing revolutionary therapies against them.
To meet unmet needs in the medical practice, DS aims to deliver innovative treatment to patients suffering from neuropathic pain especially for CIPN. To proceed with research and development toward this purpose more effectively, it seeks to recruit a partner organization with excellent research and development seeds in the field for collaboration.